Optimi Health Corp. · CSE:OPTI
Optimi Health — Investor Presentation (November 2026)
16 slides from Optimi Health's investor presentation, November 2026
Slide 1: Investor Presentation
NASDAQ: OPTH | CSE: OPTI | FSE: 8BN Investor Presentation November 2026 Naturally derived psychedelic solutions to address significant global unmet needs
Slide 2: Disclaimer & forward-looking statements
Disclaimer & forward-looking statements This presentation has been prepared by Optimi Health Corp. ("Optimi" or the "Company") for informational purposes only. It is based on information from the Company and publicly available sources, including the Company’s public filings with applicable securitie
Slide 3: Natural medicines on a path to registration
Natural medicines on a path to registration Investment highlights Phase 2 and Phase 3 trials starting Natural psilocybin (OPTI-101): Phase 2 in MDD, up to 200 patients in 2027 MDMA (OPTI-201): Phase 3 in PTSD, up to 100 patients To our knowledge, one of the only naturally extracted psilocybin in com
Slide 4: Legacy options have limited efficacy and high relapse rates
Lead program targets a large unmet need Legacy options have limited efficacy and high relapse rates4 322M People have MDD worldwide1 23M Americans experience MDD annually2 12M Americans treated for MDD in the last year2 1/3 (4M) Considered TRD (fail 2+ antidepressants)3 1. World Health Organization,
Slide 5: Clinical path to registration
Clinical path to registration Pipeline Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Milestones Dosing expected to begin OPTI-101 MDD Q1 2027; topline data expected H1 2028 Canadian trial initiation and OPTI-201 PTSD planned U.S. IND filing in 2027 OPTI-101: Naturally derived psilocybin OPTI-201:
Slide 6: OPTI-101: Psilocybin
Natural psilocybin extract OPTI-101: Psilocybin Natural extract supplied to patients in Australia What is psilocybin? Naturally occurring psychedelic compound found in certain fungi, studied for its effects on neuroplasticity and brain network activity Clinically studied for treatment-resistant depr
Slide 7: OPTI-101: Psilocybin Phase 2 clinical trial
Phase 2 clinical trial OPTI-101: Psilocybin Major depressive disorder (MDD) Supported by prior clinical data Health Canada-authorized trial, starting 2027 Ph 1 Ph 2 Ph 3 Design Endpoint Timing Patients Single supervised session Change from baseline in Dosing expected to begin Up to 200 patients with
Slide 8: OPTI-201: MDMA
MDMA capsules OPTI-201: MDMA Supplying patients in Australia and Canada What is MDMA? Psychoactive compound studied for its effects on emotional processing, fear responses and the therapeutic alliance MDMA-assisted therapy received FDA Breakthrough Therapy designation for PTSD (2017, MAPS/Lykos prog
Slide 9: OPTI-201: MDMA Phase 3 clinical trial
Phase 3 clinical trial OPTI-201: MDMA Post-traumatic stress disorder (PTSD) Supported by prior clinical data Health Canada-authorized trial, starting 2027 Ph 1 Ph 2 Ph 3 Design Endpoint Timing Patients Two supervised sessions Change from baseline in Canadian trial initiation and Up to 100, with a fo
Slide 10: What the trials unlock
The clinical opportunity What the trials unlock 1 Canada: NOC/c pathway 2 United States: FDA pathway Conditional approval for serious conditions based on promising evidence of ICH-standard Canadian data designed to support a U.S. Phase 3 effectiveness, with confirmatory studies required Executive Or
Slide 11: Australia proved the model
Proof of model Australia proved the model Nearly 5,000 doses shipped as of Q3 2026 Repeat orders scaling with distribution partners in Australia Capacity to manufacture millions of doses for export 01 02 03 04 Optimi exports from Canada to Local pharmacy delivers Patient receives treatment at DVA fu
Slide 12: Vertically integrated GMP manufacturing
How we make it Vertically integrated GMP manufacturing Cultivation & sourcing Extraction & API Formulation QC & release Export & dispensing Sterile cultivation of Psilocybe → Natural psilocybin extraction → Dose-titrated encapsulation at → HPLC-MS verification, USP → International narcotic permits;
Slide 13: How Optimi wins in each scenario
Strategic position How Optimi wins in each scenario 1 FDA approves a psilocybin drug (possible 2026–27) 2 FDA approvals slip Executive Order directs an expedited DEA scheduling review Existing supply business continues U.S. clinic infrastructure builds out Australia expands; Canada’s Special Access
Slide 14: Accomplishments & catalysts
Momentum Accomplishments & catalysts Delivered in 2026 to date Catalysts ahead Completed 2026 production of MDMA and psilocybin; Australian import permits Continued Australian expansion under the broadened prescriber framework obtained Phase 2 psilocybin trial (MDD): dosing Q1 to Q3 2027 MDMA and ps
Slide 15: Leadership
Experienced team Leadership Executives, directors, and strategic advisors who built and scaled global consumer and pharmaceutical brands JJ Wilson Dane Stevens Bryan Safarik Dr. Michael Blough Chairman Chief Executive Officer & Director Chief Operating Officer & Director Chief Clinical Development O
Slide 16: Naturally derived psychedelic solutions to address significant global unmet needs
Naturally derived psychedelic solutions to address significant global unmet needs 01 02 03 Phase 2 and 3 trials Supplying patients Low-cost natural in 2027 today supply NASDAQ: OPTH | CSE: OPTI | FSE: 8BN
Optimi Health — Investor Presentation (November 2026) on 6ix